“复旦肿瘤”自主研发人胰腺癌6基因检测试剂盒通过备案

Core Viewpoint - The "Human Pancreatic Cancer 6 Gene Mutation Detection Kit," developed by a team led by Professor Yu Xianjun from Fudan University Affiliated Tumor Hospital, has been approved by the Shanghai Municipal Drug Administration, addressing the challenges of precise diagnosis and treatment for pancreatic cancer, often referred to as the "king of cancers" due to its high malignancy and rapid progression [1][2]. Group 1 - Pancreatic cancer is characterized by high malignancy, rapid progression, and hidden early symptoms, leading to late-stage diagnosis for most patients, which significantly reduces the 5-year survival rate [1]. - Traditional detection methods focus on individual genes, limiting their ability to capture the full spectrum of genetic mutations associated with pancreatic cancer, which can hinder the development of personalized treatment plans [1][2]. - The new detection kit integrates next-generation sequencing technology and deep capture techniques, allowing for the targeted detection of six core mutation genes in pancreatic cancer pathways, achieving breakthroughs in both precision and efficiency [2]. Group 2 - The development team aims to provide rapid and accurate detection results that can be effectively implemented in clinical settings, ultimately benefiting more pancreatic cancer patients [2]. - The approval of the detection kit reflects the advantages and value of the hospital's integrated model of clinical research and treatment, positioning Fudan University Affiliated Tumor Hospital as a leading institution in precision medicine [2]. - Future plans include deepening the innovation path for key diagnostic tools led by clinical institutions, ensuring that more "Chinese solutions" and "Chinese technologies" benefit cancer patients [3].